Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers raises outlook for fiscal year 2021 after outstanding first quarter
Press release

Siemens Healthineers raises outlook for fiscal year 2021 after outstanding first quarter

Published on February 1, 2021

Siemens Healthineers AG today announced its results for the first quarter of fiscal year 2021 that ended December 31, 2020.

Q1 Fiscal Year 2021

  • Excellent start into the fiscal year with 13.3% comparable revenue growth from the prior-year quarter
  • Equipment book-to-bill ratio at a very good 1.16
  • Outstanding comparable revenue growth of 23.5% in Diagnostics – significant revenue contribution from rapid COVID-19 anti-gen tests in EMEA and return to growth in the core business
  • High comparable revenue growth of 9.3% in Imaging and 6.3% in Advanced Therapies; very good development in EMEA and Asia, Australia
  • High profitability: Adjusted EBIT margin increases by 550 bps year-over-year to 19.1%
  • Adjusted basic earnings per share up to €0.49, from €0.36 in the prior-year quarter
  • Free cash flow by far more than doubled year-over-year to €668 million 

Updated Outlook for Fiscal Year 2021

  • Comparable revenue growth of 8% to 12% expected (previously 5% to 8%)
  • Adjusted basic earnings per share between €1.63 and €1.82 (previously €1.58 to €1.72)

Link to the related press feature

»We started into the new fiscal year with an outstanding quarter. This was made possible through the tireless efforts of the entire Siemens Healthineers team. Our comprehensive portfolio of imaging and diagnostics enables us to make important contributions in helping healthcare providers around the globe to master this pandemic successfully, impressively underlining our impact on society. Against the backdrop of the positive developments in the first quarter, we are raising our outlook for fiscal year

2021.« 

Bernd Montag
CEO of Siemens Healthineers AG

Download quarterly statement(pdf, 287.50 KB)

Siemens Healthineers 2021

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide. Further information is available at www.siemens-healthineers.com.